The roles of cellular and molecular components of a hematoma at early stage of bone healing. (31st January 2018)

• Record Type: Journal Article
• Authors: Shiu, Hoi Ting; Leung, Ping Chung; Ko, Chun Hay
• Is Part Of: Journal of tissue engineering and regenerative medicine. Volume 12:Number 4(2018)
• Page Start: e1911
• Page End: e1925
• Publication Date: 2018-01-31
• Subjects: blood clot formation -- coagulation -- complement -- erythrocyte -- fibrin network -- leukocyte -- platelet -- platelet‐derived growth factor; Tissue engineering -- Periodicals; Regeneration (Biology) -- Periodicals; 610.28
• DOI: 10.1002/term.2622
• Languages: English
• ISSNs: 1932-6254

Abstract

Abstract: Bone healing is a complex repair process that commences with the formation of a blood clot at the injured bone, termed hematoma. It has evidenced that a lack of a stable hematoma causes delayed bone healing or non‐union. The hematoma at the injured bone constitutes the early healing microenvironment. It appears to dictate healing pathways that ends in a regenerative bone. However, the hematoma is often clinically removed from the damaged site. Conversely, blood‐derived products have been used in bone tissue engineering for treating critical sized defects, including fibrin gels and platelet‐rich plasma. A second generation of platelet concentrate that is based on leukocyte and fibrin content has also been developed and introduced in market. Conflicting effect of these products in bone repair are reported. We propose that the bone healing response becomes dysregulated if the blood response and subsequent formation and properties of a hematoma are altered. This review focuses on the central structural, cellular, and molecular components of a fracture hematoma, with a major emphasis on their roles in regulating bone healing mechanism, and their interactions with mesenchymal stem cells. New angles towards a better understanding of these factors and relevant mechanisms involved at the beginning of bone healing may help to clarify limited or adverse effects of blood‐derived products on bone repair. We emphasize that the recreation of an early hematoma niche with critical compositions might emerge as a viable therapeutic strategy for enhanced skeletal tissue engineering.